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Running Title: Bariatric surgery and predicted CV risk 
Abstract  
Background and Aims 
Cardiovascular (CV) risk equations are routinely used to predict risk in non-bariatric populations but 
have not been studied in depth in patients undergoing bariatric surgery and specifically those with 
impaired glucose regulation. The aim of this pilot study was to investigate changes in the 10-year and 
lifetime predicted CV risk in subjects with impaired glucose regulation before, 1 month, 6 months and 
5 years after bariatric surgery.  
 
Method and Results 
A non-randomized prospective study of 45 participants with impaired glucose regulation undergoing 
temporal assessments during follow-up. Body weight, body mass index (BMI), blood pressure, lipid 
profile and HbA1c were recorded pre-operatively, 1 month, 6 months and 5 years post-operatively. 
Preoperative and postoperative predicted CV risk was calculated using the QRISK2, QRISK lifetime and 
JBS3 calculators.  
Follow-up rates were 93%, 91% and 71% at 1 month, 6 months and 5 years respectively. The sample 
had a mean age of 48.8 ±7.0 years, a mean BMI of 53.9 ±11.1kg/m2, and a mean HbA1c of 7.5 ±1.7%. 
The predicted 10-year QRISK2 score decreased by 35%, 54% and 24% at 1 month, 6 months and 5 
years respectively (P<0.001). The predicted lifetime risk also decreased with the greatest reduction 
(24.5% with QRISK lifetime and 26.7% with JBS3 lifetime score) observed at 5 years even though the 
subjects were 5 years older.  
 
Conclusion 
Bariatric surgery in patients with impaired glucose regulation is associated with a significant reduction 
in predicted 10-year and lifetime CV risk in a population that was 5 years older compared to baseline.  
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1. Introduction  
Cardiovascular disease (CVD) including coronary heart disease (CHD) and stroke is a leading cause of 
mortality 1 with obesity being an independent and modifiable risk factor. Sjöström et al, reported that 
bariatric surgery was associated with a reduction in cardiovascular (CV) events in obese subjects 2. 
However, a recent meta-analysis concluded that uncertainty remains regarding the effects of bariatric 
surgery on long-term CV events 3. One method to predict the long-term CV outcome following bariatric 
surgery is to use a validated risk prediction tool. CV risk assessment tools are widely used to identify 
high-risk individuals and to implement timely lifestyle and therapeutic interventions for the primary 
prevention of CVD. Most risk prediction methods provide an absolute 10-year CV risk estimate and 
several studies have demonstrated that bariatric surgery is associated with a reduction in CV risk 
scores 4-8. However, risk calculators used in most of these studies do not include body mass index 
(BMI) or obesity as risk factors. These CV risk calculators include the Framingham risk score (FRS), the 
Prospective Cardiovascular Munster Heart Study (PROCAM) score and the United Kingdom 
Prospective Diabetes Study (UKPDS) Risk engine 4, 6-9. In addition, many studies have focused on CHD 
risk rather than CVD risk 8, 9; the study samples have included the entire spectrum of bariatric patients, 
with little focus on those impaired glucose regulation 5-9; and the follow-up has also been relatively 
short 5-9. The study by Vogel et al, which consisted of 109 Roux-en-Y gastric bypass (RYGB) patients, 
reported that the Framingham CHD risk score decreased by 39% in men and 25% in women (P<0.001) 
at 17 months following surgery 8. Torquati et al, also observed a 50% reduction in the Framingham 
CHD risk score at 1 year following RYGB 9. CVD risk is a continuum and as such the consequences might 
not be observed for a significant period of time. Marma et al, showed that approximately 67% of adults 
in the United States with a low 10-year CVD risk had a high lifetime predicted risk 10. A low 10-year but 
high lifetime CVD risk is more common in women and in younger age groups because age and gender 
are two of the main determinants in CVD risk prediction models 10, 11. Morbid obesity and bariatric 
surgical procedures are more frequent in females and younger age groups (<50 years), with no fewer 
than 70% of participants in the Swedish Obese Subjects Study (SOS) being female with a mean age of 
47 years 3, 12. To date, no studies have examined the effect of bariatric surgery on the predicted lifetime 
CVD risk.  
 
The aim of this pilot study was to investigate changes in the temporal 10-year and the lifetime 
predicted CV risk in subjects with impaired glucose regulation preoperatively and 1 month, 6 months 
and 5 years following bariatric surgery by using the QRESEARCH Cardiovascular Risk Algorithm 
(QRISK2), QRISK lifetime and Joint British Societies 3 (JBS3) score. The QRISK scores and JBS3 score are 
developed and validated in the United Kingdom and include BMI as a variable in their calculation 11, 13-
15.  
 
2. Methods 
2.1 Participants 
Approval for the study was obtained from the Local Research Ethics Committee (South West Wales; 
LREC reference 06/WMW02/7) and ABM University Health Board. Participants were identified and 
recruited from patients undergoing a planned bariatric surgical procedure in our centre. Entry criteria 
at the outset included: - both genders, age 20-60 years, body mass index (BMI) >40kg/m2 and 
physically fit for surgery. All subjects had previously diagnosed type 2 diabetes, or diagnosed during 
an oral 75g glucose tolerance test (OGTT) at the start of the study according to American Diabetes 
Association (ADA) criteria 16 or impaired glucose tolerance according to ADA criteria 16. All participants 
were recruited preoperatively and followed-up post operatively at 1 month, 6 months and 5 years. 
This study sample has been previously described 17-19. 
 
2.2 Data collection 
Data was collected at baseline (preoperatively), 1 and 6 months, and 5-years postoperatively. Age, 
sex, ethnicity, address, medications, diabetes, cigarette smoking, family history of CVD, relevant past 
medical history were self-reported via standardised questionnaire. Height and weight were measured 
according to local standard protocol, and BMI was calculated as kg/m2. The percent excess weight loss 
(%EWL) was calculated by using the Ideal body weight at a BMI of 25kg/m2 20. A single measurement 
of systolic and diastolic blood pressure was obtained by the same trained registered nurse. Glucose, 
haemoglobin A1c (HbA1c), creatinine, estimated glomerular filtration rate (eGFR), lipid profile [total 
cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), 
and triglyceride] were analysed within the local hospital accredited laboratory. Diabetes remission is 
defined as:- (i) complete remission with a HbA1c <6% and fasting blood glucose <5.6 mmol/L and off 
medication (ii) partial remission  with a HbA1c 6-6.4% and fasting blood glucose 5.6-6.9 mmol/L and 
off medication 21.  
 
2.3 Cardiovascular risk estimation 
Cardiovascular risk, both pre- and post-operatively were calculated by using online calculators: 
QRISK2-2016 (www.qrisk.org/index.php), QRISK lifetime (www.qrisk.org/lifetime/index.php), 
accessed  01/05/2016 and JBS3 (www.jbs3risk.com/pages/risk_calculator.htm), accessed 
15/04/2016.  
 
2.4 Statistical analysis 
Statistical analysis was performed using SPSS (version 22, SPSS Inc., Chicago). Continuous data with a 
normal distribution are presented as mean and standard deviation, and data which did not have a 
normal distribution are described as median and interquartile range. A paired samples t-test, one-way 
repeated measure ANOVA and independent-samples t-test were used for continuous variables with a 
normal distribution and the Friedman’s test, the Wilcoxon signed rank test and the Mann-Whitney U 
test were used for continuous variables which did not have a normal distribution. The Chi-squared 
test was used for analysis of categorical variables. In all cases a P≤0.05 was considered statistically 
significant.  
 
3. Results 
3.1 Participant characteristics  
Of the 49 participants, 4 had pre-existing CVD preoperatively and were excluded from further analysis. 
Of the remaining 45 subjects, 42 and 41 participants attended the 1 and 6-month follow-up post-
operative visits. At the time of manuscript preparation (February 2016), 20 participants had attended 
a 5-year follow up visit; 12 participants had attended a follow-up visit with their general practitioners; 
8 were lost to follow-up; and 5 were deceased (Figure 1). At 5 years, data for clinical measures of 
obesity were available for 27 participants, HbA1c for 31 participants, lipid profile for 30 participants 
and medication history for 36 participants. Within the sample, 24 participants had undergone a 
laparoscopic sleeve gastrectomy, 12 a biliopancreatic diversion, 6 a RYGB and 3 a laparoscopic 
adjustable gastric banding.  
 
3.2 Changes in clinical measures of obesity  
Table 1 shows the changes in clinical measures of obesity at 1 month, 6 months and 5 years following 
bariatric surgery. The greatest changes were seen at 6 months postoperatively and these were 
maintained at 5 years. The maximum %EWL (45 ±18%) was achieved at 6 month following surgery 
(P<0.001).  
 
3.3 Changes in cardiovascular risk factors  
Table 1 shows the changes in risk factors for all available subjects at 1 month, 6 months and 5 years 
after bariatric surgery. Significant reductions in both systolic and diastolic blood pressures were 
observed at 1 month. The mean systolic blood pressure decreased by 10.9 ±4.3mmHg (P=0.02) and 
the mean diastolic blood pressure by 7.3 ±2.5mmHg (P=0.009) at 1 month. No significant changes in 
blood pressure were recorded at 6 months and 5 year visits. 
 
Total serum cholesterol concentration showed a decrease at 1 month but an increase at 5 years 
(P=0.034). HDL cholesterol showed a similar trend to that of total cholesterol (P<0.001). Significant 
changes in serum triglyceride level were observed at 6 months but there was no significant change in 
LDL cholesterol level. 
 
The greatest change in mean HbA1c was observed at 6 months (P<0.001). Mean HbA1c decreased by 
1.0%, 1.7% and 1.0% at 1 month, 6 months and 5 years respectively (P<0.001). Of those patients with 
type 2 diabetes, 71% achieved the National Institute of Health and Care Excellence (NICE) 
recommended target HbA1c of 7% at 5 years after bariatric surgery. The prevalence of complete 
remission of type 2 diabetes at 1 and 6 months and 5 years postoperatively were 27%, 44.7% and 
35.5%, respectively (P<0.001). The prevalence of partial remission of T2DM was 18%, 8% and 18.5% 
at 1 month, 6 months and 5 years respectively (P<0.001).  
 
3.4 Changes in medications 
Table 2 shows the changes in medication following bariatric surgery. The requirement for diabetes 
medication was significantly lower following surgery. A decrease in antihypertensive medication was 
also observed (68.9% at baseline versus 39.4% at 5 years), but this was not statistically significant 
(P=0.463). The proportion of participants non longer requiring lipid-lowering medication was greatest 
at 5 years (35.6% at baseline versus 63.9% at 5 years) but this was not again statistically significant 
(P=0.0728).   
 
3.5 Changes in predicted 10-year cardiovascular risk  
The preoperative and postoperative QRISK2 scores were calculated using the age at the time of the 
visit. A significant reduction in 10-year predicted QRISK2 scores were observed across the temporal 
time points (P<0.001). Table 3 shows the percentage change in absolute risk and relative risk. The 
QRISK2 calculator also provides relative risk, which is calculated by dividing the subject’s predicted 
risk score by a healthy subject’s risk. A healthy person is defined as an individual with same age, sex 
and ethnicity; no adverse clinical indicators; a BMI of 25kg/m2; a systolic blood pressure of 125mmHg; 
and a cholesterol ratio of 4. Risk groups were categorised as follows: a score of <10% as low risk; a 
score of 10-19% as moderate; and a score of ≥20% as high risk. Chi-squared analysis revealed there 
was a significant difference in distribution of low, moderate and high-risk groups before and after 
bariatric surgery (P=0.042) (Figure 2).  
 
Table 3 shows changes in the 10-year JBS3 score preoperatively, 1 and 6 months, and 5 years after 
bariatric surgery. The predicted 10-year JBS3 score was lower at 1 and 6 months, but at 5 years the 
score was similar to the preoperative level. After adjusting for age, a significant change in 10-year JBS3 
score was observed at 5 years (P<0.001). No significant difference in the distribution of risk groups 
before and after bariatric surgery was observed.  
 
3.6 Changes in predicted lifetime cardiovascular risk  
We observed that bariatric surgery had a positive impact not only on predicted 10-year CVD risk but 
also on the lifetime CVD risk. Table 4 shows changes in the QRISK lifetime score and JBS3 lifetime 
score. The maximum decrease in predicted lifetime CVD risk was observed at 5 years for both risk 
assessment models. Mean lifetime QRISK score decreased by 10.3%, 15.9% and 24.5% at 1 and 6 
months, and 5 years respectively (P<0.001). Similar observations were seen for the lifetime JBS3 score: 
11.8% reduction at 1 month; 15.3% reduction at 6 months; and 26.7% reduction at 5 years (P<0.001).  
 
3.7 Baseline predicted CVD risk scores between attenders and non-attenders 
Table 5 shows baseline predicted CVD risk scores between two groups defined by their 5-year status. 
Attenders were those who had attended follow-up visit at 5 years. Non-attenders included those who 
were lost to follow-up or deceased. There were no differences in baseline risk scores between two 
groups.  
4. Discussion 
Our pilot study has demonstrated that bariatric surgery is associated with a reduction in predicted 10-
year CVD risk and predicted lifetime CVD risk despite the patients being years older. To our knowledge, 
no previous studies have examined the effect of bariatric surgery on predicted lifetime cardiovascular 
risk in individuals with impaired glucose regulation. Since the long-term effects of bariatric surgery on 
CVD events are unclear, there is a need to investigate the effect on predicted lifetime CVD risk 
following bariatric surgery. The 10-year CVD risk alone might miss a proportion of those with a high 
lifetime risk. Mackey et al, reported that 76% of bariatric patients with a low 10-year predicted risk 
had a high lifetime CVD risk 22. We observed that bariatric surgery was associated with a continuous 
decrease in the lifetime CVD risk. Of note, age alone is a non-modifiable risk factor for the 
development of CVD. In a cohort of 3.6 million individuals age ≥40 years, the prevalence of any 
vascular disease increased significantly with each decade of life: 2% in 50 year olds, 3.5% in 60 year 
olds, 7.1% in 70 year olds, 13% in 80 year olds, and 22.3% in 90 year olds 23. In our study, the maximum 
reduction in lifetime CVD risk (up to 26% reduction) was observed at 5 years despite the participants 
being 5 years older. We also observed a reduction in 10-year CVD risk: 54% reduction in QRISK2 score 
at 6 months and 24% reduction at 5 years. The relative risk reduction in QRISK2 was more pronounced 
at 5 years compared to absolute risk reduction (59% versus 24%). A significant reduction in predicted 
10-year JBS3 score was observed at 5 years after adjusting age to baseline. Of interest, several studies 
have demonstrated that bariatric surgery is associated with a reduction in predicted 10-year CVD risk. 
The study by Batsis et al 7, which included 197 RYGB patients and 163 control patients, used the FRS 
and the Prospective Cardiovascular Munster Heart Study (PROCAM) risk score. The 10-year FRS CVD 
risk score was lower at 3.3 years in the surgical group (from 7.0 to 3.5%; P<0.001) compared to the 
control group (from 7.1 to 6.5%; P<0.001). The PROCAM score was also lower in the surgical group 
(4.1 to 2.0%; P<0.001) when compared to the control group (4.4 to 3.8%; P=0.08). Aminian et al, 
demonstrated that RYGB was associated with a relative risk reduction of 27% for 10-year overall risk 
of CHD, stroke, and peripheral vascular disease; 20% for 10-year risk of CHD; 40% for 10-year risk of 
myocardial infarction; 42% for 10-year risk of stroke; and 47% for 4-year risk of intermittent 
claudication in a cohort of 131 diabetic patients at 6 years 4. Radwan et al reported that QRISK2 score 
were significantly lower in a cohort of 250 bariatric surgical patients at 24 months 5. 
 
The QRISK2 algorithm has been developed using routinely collected data from Primary Care practices 
across England and Wales. The study cohort consisted of 2.3 million patients aged 35-74 years from 
531 practices. Validation studies demonstrated that QRISK2 identified high-risk patients more 
accurately than the modified Framingham score in the UK population 14, 24. Recent guidance from NICE 
recommends QRISK2 as the CVD risk assessment tool 25. QRISK2-2016 utilises the following variables:- 
age, gender, ethnicity, Townsend score, smoking status, diabetes mellitus, family history of CVD, 
chronic kidney disease, atrial fibrillation, rheumatoid arthritis, blood pressure treatment, systolic 
blood pressure, total cholesterol, HDL-C and BMI 26. Endpoints assessed in QRIKS2 are fatal and non-
fatal myocardial infarct, angina, coronary revascularization, fatal and non-fatal stroke, transient 
ischaemic attack and intermittent claudication. The QRISK lifetime 14 uses the same variables as 
QRISK2 and calculates cardiovascular risk up to 95 years of age. The JBS3 risk calculator was also 
developed in the UK and released in 2014. Variables used and endpoints assessed in JBS3 are similar 
as those in QRISK2 11.  
 
Bariatric surgery aims to provide improvement in CVD risk factors and long-term weight loss. In our 
current study we observed a reduction of 44% in %EWL, 22.7% in body weight, 35.5% in prevalence 
of diabetes remission, a reduced proportion of glucose lowering medication, and improvement in CV 
biomarkers with an increase in HDL-C, and a decrease in total cholesterol to HDL-C ratio at 5 years. 
The increase in total cholesterol may be explained by the increase in HDL-C and the decrease in total 
to HDL-C ratio. A reduction in both systolic and diastolic blood pressure, lower anti-hypertensive 
medication and lipid lowering medication were observed but the differences were not statistically 
significant.  
One of the limitations of our study is that these risk assessment tools have not previously been 
validated specifically in those with impaired glucose regulation and morbid obesity. Another limitation 
is the drop-out rate at 5 years. However, we observed no differences in baseline risk scores between 
participants with follow-up and those with lost-to follow-up or were deceased. In addition, significant 
reductions in risk scores were observed in the baseline-observation-carried-forward analysis (data not 
shown). A further limitation is the small number of patients included. Nevertheless, this study is the 
first study to examine the predicted lifetime CVD risk in bariatric surgical patients with impaired 
glucose regulation. We also have temporal measures from preoperative to 1 month, 6 months and 5 
years postoperative period.  
 
5. Conclusion 
In conclusion, the results of this pilot study indicate that bariatric surgery in patients with impaired 
glucose regulation is associated with a significant reduction in predicted 10-year and lifetime CVD risk 
in a population that was on average 5 years older compared to baseline. Furthermore, we observed 
long-term weight loss, excellent control of diabetes and less of a requirement for hypoglycaemic 
agents. This is a pilot study with a small sample size, and hence further studies with larger numbers 
are warranted.  
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Table 1. Changes in clinical measure of obesity and risk factors at 1 month, 6 months and 5 years following bariatric surgery 
Clinical measure Baseline 
(n=45) 
1 month 
(n=42) 
ap 6 months 
(n=41) 
bp 5 years 
(n=32) 
cp 
Weight (kg) 150.4 ±34.7 131.6 ±28.3 <0.001 115.2 ±26.1 <0.001 116.2 ±30.1 <0.001 
BMI (kg/m2) 54  ±13 47 ±9 <0.001 41 ±9 <0.001 43 ±11 <0.001 
%EWL   24 ±10 <0.001 45 ±18 <0.001 44 ±28 <0.001 
Waist (cm) 138 ±17 130 ±20 0.001 120 ±19 <0.001 122 ±21 0.003 
Systolic blood pressure (mm Hg) 136 ±17 125 ±15 0.02 132 ±14 0.23 133 ±15 0.422 
Diastolic blood pressure (mm Hg) 79 ±9 71 ±8 0.009 76 ±10 0.239 75 ±10 0.219 
HbA1c (%) 7.3 ±1.6 6.3 ±0.9 <0.001 5.9 ±1.0 <0.001 6.3 ±1.3 <0.001 
HbA1c (mmol/mol) 56.5 ±18 45.4 ±9.3 0.001 41.2 ±11.1 <0.001 45.1 ±13.8 <0.001 
Total cholesterol (mmol/L) 4.5 ±0.9 4.0 ±0.9 0.035 4.4 ±1.1 0.610 4.7 ±1.2 0.514 
HDL cholesterol (mmol/L)* 1.2 (1.0-1.4) 1.1 (0.9-1.3) 0.019 1.2 (1.0-1.35) 1 1.4 (1.0-1.7) 0.031 
TC:HDL-C* 3.5 (2.9-4.6) 3.7 (2.8-4.6) 1 3.3 (3.0-4.5) 1 3.00 (2.3-4.0) 0.052 
LDL cholesterol (mmol/L) 2.4 ±0.7 2.2 ±0.8 0.324 2.5 ±1.0 0.758 2.4 ±0.9 0.820 
Triglyceride (mmol/L)* 1.5 (1.1-2.4) 1.4 (1.1-2.0) 1 1.2 (1.0-1.6) 0.031 1.3 (0.9-1.7) 1 
Data are presented as mean ±SD. 
*Data are presented as median and interquartile range.  
ap-value comparing baseline with 1 month 
bp-value comparing baseline with 6 months 
cp-value comparing baseline with 5 years 
BMI: body mass index; % EWL: percentage excess weight loss. 
Table 2. Changes in medications 
 
 Baseline 1 month 6 months 5 years P value 
Anti-diabetic medications 
n 40 38 35 30 0.00073 
None (%) 8 (20) 20 (52.6) 21 (60) 19 (63.3) 
Oral agents (%) 18 (45) 14 (36.8) 11 (31.4) 7 (23.3) 
Insulin (%) 9 (22.5) 3 (7.9) 3 (8.6) 1 (3.3) 
GLP-1 (%) 8 (20) 1 (2.6) 0 3 (10) 
Anti-hypertensive medications 
n 45 38 35 33 0.463 
None (%) 14 (31.1) 18 (47.4) 18 (51.4) 20 (60.6) 
Monotherapy (%) 13 (28.9) 10 (26.3) 7 (20) 6 (18.2) 
Dual therapy (%) 11 (24.4) 6 (17.1) 7 (20) 3 (9.1) 
Combinations (%) 7 (15.6) 4 (10.5) 3 (8.6) 4 (12.1) 
Lipid lowering medications 
n 45 38 36 36 0.0728 
No (%) 16 (35.6) 19 (50) 20 (55.6) 23 (63.9) 
Yes (%) 29 (64.4) 19 (50) 16 (44.4) 13 (36.1) 
P values calculated from Chi-squared analysis. 
 
Table 3. Changes in predicted 10-year CVD risk at 1 month, 6 months, and 5 years 
 QRISK2 (n=29) QRISK2 (n=29) JBS3 (n=27) 
 Absolute 
risk 
Change 
from 
baseline* 
% change 
from 
baseline 
P value Relative 
risk 
Change 
from 
baseline* 
% change 
from 
baseline 
P value  Change 
from 
baseline* 
% change 
from 
baseline 
P value 
Baseline 15.1 
(9.8-17.4) 
   4.8 
(2.9-9.7) 
   8.1 
(5.1-11.3) 
   
1 month 9.7 
(5.0-12.8) 
4.9 
(0.2-6.7) 
35 
(4-59) 
0.009 3.1 
(1.6-6.8) 
1.7 
(0.1-3.9) 
35 
(2-59) 
0.026 4.8 
(3.1-7.5) 
1.3 
(0.2-4.3) 
29 
(3-40) 
0.001 
6 months 7.4 
(3.0-14.2) 
4.8 
(1.4-9.5) 
54 
(11-69) 
<0.001 2.3 
(1.4-3.6) 
1.7 
(0.5-5.2) 
52 
(10-69) 
0.001 4.9 
(3.0-8.2) 
1.9 
(0.9-3.8) 
35 
(7-49) 
0.001 
5 years 9.1 
(5.9-14.2) 
2.7 
(0.6-7.9) 
24 
(5.5-53) 
0.022 1.8 
(1.2-3.1) 
3.2 
(1.0-5.5) 
59 
(35-75) 
<0.001 8.0 
(4.4-12) 
0 
(-1.2,2.4) 
0 
(-15,36) 
1.0 
5 years 
(age 
adjusted) 
        5.1 
(2.3-12.2) 
2.0 
(1.0-5.4) 
32 
(18-54) 
<0.001 
Table 4. Changes in predicted lifetime CVD risk at 1 month, 6 months and 5 years 
 QRISK lifetime (n=27) JBS3 lifetime (n=27) 
 Mean ± SD Mean difference 
(95%CI) 
% reduction Mean ± SD Mean difference 
(95%CI) 
% reduction 
Baseline 45.8±12.2   48.4±13.1   
1 month 41.1±12.7 4.7 (2.2-7.1)* 10.3 42.7±13.5 5.7 (3.1-8.4)* 11.8 
6 months 38.5±11.7 7.3 (4.8-9.8)* 15.9 41.0±12.9 7.4 (4.5-10.3)* 15.3 
5 years 34.6±8.7 11.2 (7.1-15.3)* 24.5 35.4±8.8 12.9 (7.4-18.5)* 26.7 
Data are presented as mean ±SD.  
* A one-way repeated measures ANOVA followed by paired t-test revealed significant changes in predicted lifetime CVD score over time 
(p<0.001).  
Table 5. Baseline risk scores between attenders and non-attenders  
 
Risk score Attenders (n=32) Non-attenders (n=13) P value 
QRISK2* 12.8 (9.7-17.4) 14.9 (7.1-19.5) 0.822 
JBS3 (10-year)* 6.6 (4.0-11.0) 5.0 (3.6-9.6) 0.462 
QRISK lifetime 45.1 ±11.3 41.8 ±9.8 0.352 
JBS3 lifetime 47.9 ±11.8 48.1 ±11.8 0.951 
Data are presented as mean ±SD.  
* Data are presented as median and interquartile range.  
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Figure Legends 
Figure 1. Flow chart showing number of attenders and non-attenders at each visit 
LTF: Loss to follow-up 
 
Figure 2. Distribution of risk groups classified by QRISK2 score, before and 1 month, 6 
months and 5 years after bariatric surgery  
Chi-squared analysis revealed a significant difference in distribution of risk groups before 
and after bariatric surgery (P=0.042). 
Low risk group: score <10; Moderate risk group: score 10-19; High risk group: score ≥20. 
 
